Form 4: ANI Pharmaceuticals CFO Executes Stock Option Plan

ANI Pharmaceuticals SVP & CFO Stephen P. Carey exercised options and sold 3,312 shares of common stock under a 10b5-1 plan.

Summary

• SVP & CFO Stephen P. Carey exercised 3,312 stock options at a strike price of $49.51.
• Following the exercise, the reporting person sold the 3,312 shares at a market price of $80.00 per share.
• The transactions were executed on June 5, 2026, pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.
• The reporting person retains beneficial ownership of 180,393 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was conducted under a pre-established 10b5-1 plan and represents a small portion of the executive's total holdings.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a systematic approach to equity management rather than reactive selling.

Negatives

• The transaction represents a divestment of equity by a key member of the executive leadership team.

Risks

• Executive stock sales can sometimes be perceived negatively by the market as a signal of management's view on current valuation.

Future Outlook

No forward-looking guidance provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is a standard corporate governance practice for executives to manage personal liquidity and is generally viewed as neutral by institutional investors.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest or accusations of insider trading.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small percentage of the CFO's total equity stake.

Key Dates

Keywords

ANIP, ANI Pharmaceuticals, Insider Trading, Form 4, CFO, Stock Options